Company News

Japan-based Dainippon Sumitomo Pharma (DSP) will acquire Massachusetts-based Sepracor for approximately $2.6 billion, the companies announced in a joint statement. Sepracor will become a subsidiary of DSP, and retain its name, branding and intellectual property rights, as well as maintain its operations based in Marlborough, MA and Canada. Sepracor Pharmaceuticals, a subsidiary of Sepracor, reported revenues of $1.3 billion for 2008, due in large part to sales of Lunesta, a popular sleep aid.

Abbott
announced that it will acquire California-based Visiogen, a privately held developer of ocular products and technologies, for $400 million in cash. Through the acquisition, Abbott will gain a next-generation accommodating intraocular lens technology, to address presbyopia for cataract patients, according to a company release.

The AIDS Healthcare Foundation (AHF), a Los Angeles-based non-profit healthcare provider, launched a campaign against Merck accusing the company of “criminal AIDS drug pricing” on Isentress. Merck recently gained an expanded use for Isentress, which is now approved as a first-line therapy. The AHF will mail mock-up “WANTED” postcards depicting Merck CEO Richard T. Clark as a criminal to residents of Whitehouse Station, NJ, where Merck is headquartered. Isentress is the first of a new class of HIV/AIDS treatments called integrase inhibitors. According to an AHF statement, the product's retail price per patient, per year, comes to $12,864, making it “the most expensive antiretroviral recommended by the US Department of Health and Human Services for therapy naive patients.”

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.